[
  {
    "ts": "2025-12-22T08:58:00+00:00",
    "headline": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
    "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
    "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
      "content": {
        "id": "2c160554-0225-3523-ac6e-41ac27dc9837",
        "contentType": "STORY",
        "title": "Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?",
        "description": "",
        "summary": "Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader.",
        "pubDate": "2025-12-22T08:58:00Z",
        "displayTime": "2025-12-22T08:58:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29",
          "originalWidth": 1200,
          "originalHeight": 801,
          "caption": "A medical professional filling a needle from a bottle of medicine.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4FLKocTE8Dy4an3gq.W46A--~B/aD04MDE7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 1200,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OjZI_UgWLI8P7SE8GyR7Cw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/34be29d992e20b626208f7610cd6ad29.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/22/forget-novo-nordisk-buy-high-yield-drug-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-novo-nordisk-buy-magnificent-085800517.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T09:59:07+00:00",
    "headline": "Abivax soars on report of Eli Lilly meeting French officials over possible deal",
    "summary": "Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.",
    "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b3c9723-f11f-35e7-b056-b8543a20195a",
      "content": {
        "id": "0b3c9723-f11f-35e7-b056-b8543a20195a",
        "contentType": "STORY",
        "title": "Abivax soars on report of Eli Lilly meeting French officials over possible deal",
        "description": "",
        "summary": "Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.",
        "pubDate": "2025-12-22T09:59:07Z",
        "displayTime": "2025-12-22T09:59:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abivax-soars-report-eli-lilly-095907134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AAVXF"
            },
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ADVM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T11:50:10+00:00",
    "headline": "Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)",
    "summary": "Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]",
    "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2c2bc334-972a-3bd4-b3f5-66a77de011fd",
      "content": {
        "id": "2c2bc334-972a-3bd4-b3f5-66a77de011fd",
        "contentType": "STORY",
        "title": "Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)",
        "description": "",
        "summary": "Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]",
        "pubDate": "2025-12-22T11:50:10Z",
        "displayTime": "2025-12-22T11:50:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c",
          "originalWidth": 1000,
          "originalHeight": 668,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_ZfoJ4THRdWEUJIk6yi7sg--~B/aD02Njg7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c.cf.webp",
              "width": 1000,
              "height": 668,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3VSaBedNr1qF1wBLp8RjEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c7cbbfaa5b33f51cedabc8bab9f6be5c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-h-c-wainwright-sees-115010878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T04:37:24+00:00",
    "headline": "2 Profitable Stocks with Exciting Potential and 1 Facing Challenges",
    "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
    "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "f5de3703-479f-3323-8de8-e339f117c8f6",
      "content": {
        "id": "f5de3703-479f-3323-8de8-e339f117c8f6",
        "contentType": "STORY",
        "title": "2 Profitable Stocks with Exciting Potential and 1 Facing Challenges",
        "description": "",
        "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
        "pubDate": "2025-12-22T04:37:24Z",
        "displayTime": "2025-12-22T04:37:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "UNP Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/V4xbv_.Ir4Zn.ad7Q_QE.g--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UUEyrLCA7DVNbn9y2xfQ8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/43ca9a61a8734ba68ffae324770ff9e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-exciting-potential-043724219.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ARES"
            },
            {
              "symbol": "UNP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:30:00+00:00",
    "headline": "CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies",
    "summary": "-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun",
    "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e4655848-37df-34c5-8e9e-c819e2bb7596",
      "content": {
        "id": "e4655848-37df-34c5-8e9e-c819e2bb7596",
        "contentType": "STORY",
        "title": "CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies",
        "description": "",
        "summary": "-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun",
        "pubDate": "2025-12-22T13:30:00Z",
        "displayTime": "2025-12-22T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad",
          "originalWidth": 1800,
          "originalHeight": 1957,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mnPsJEczvucHirpNfZ3Hpg--~B/aD0xOTU3O3c9MTgwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 1800,
              "height": 1957,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8jC0wMX28ixyv6Mj1oYr_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/1aff8de1b43a5c2c983997aa98d58aad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crispr-therapeutics-provides-broad-zugocaptagene-133000753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T14:23:01+00:00",
    "headline": "Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market",
    "summary": "Weight-Loss Drugs Face a 2026 Inflection Point. Here's What Changes Next",
    "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-why-142301216.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "1f5a383d-92ff-3ce9-8653-0e5d9bcd34b3",
      "content": {
        "id": "1f5a383d-92ff-3ce9-8653-0e5d9bcd34b3",
        "contentType": "STORY",
        "title": "Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market",
        "description": "",
        "summary": "Weight-Loss Drugs Face a 2026 Inflection Point. Here's What Changes Next",
        "pubDate": "2025-12-22T14:23:01Z",
        "displayTime": "2025-12-22T14:23:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c",
          "originalWidth": 6382,
          "originalHeight": 4786,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Klfzvp39.soPeoaiqKcS3w--~B/aD00Nzg2O3c9NjM4MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 6382,
              "height": 4786,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W9CEpukOrGiNcDXN4UIi7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/434a82c75d97e3a5a22898838638d64c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-why-142301216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-vs-novo-nordisk-why-142301216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T14:00:48+00:00",
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Renewed Tech Confidence",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad",
    "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-140048640.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "43b08ef3-d933-3dc0-bc1d-7d84e0c11194",
      "content": {
        "id": "43b08ef3-d933-3dc0-bc1d-7d84e0c11194",
        "contentType": "STORY",
        "title": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Renewed Tech Confidence",
        "description": "",
        "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad",
        "pubDate": "2025-12-22T14:00:48Z",
        "displayTime": "2025-12-22T14:00:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-140048640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-140048640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "BITO"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:42:17+00:00",
    "headline": "BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s […]",
    "url": "https://finance.yahoo.com/news/bofa-maintains-buy-eli-lilly-134217588.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f7f4d4ed-9c75-3536-a61e-b6d33fd0bfa9",
      "content": {
        "id": "f7f4d4ed-9c75-3536-a61e-b6d33fd0bfa9",
        "contentType": "STORY",
        "title": "BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s […]",
        "pubDate": "2025-12-22T13:42:17Z",
        "displayTime": "2025-12-22T13:42:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-maintains-buy-eli-lilly-134217588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-maintains-buy-eli-lilly-134217588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:39:58+00:00",
    "headline": "Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. On December 12, Eli Lilly and Company provided updated data […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-133958343.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2d7eecf1-a50c-35c8-b66f-965b64398113",
      "content": {
        "id": "2d7eecf1-a50c-35c8-b66f-965b64398113",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. On December 12, Eli Lilly and Company provided updated data […]",
        "pubDate": "2025-12-22T13:39:58Z",
        "displayTime": "2025-12-22T13:39:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-133958343.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-announces-133958343.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T08:56:00+00:00",
    "headline": "Radiopharmaceutical specialist Aktis seeks an IPO",
    "summary": "The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.",
    "url": "https://www.biopharmadive.com/news/aktis-oncology-biotech-ipo-radiopharmaceuticals-nectin-4/808472/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "5f67a420-c19c-3e35-9c4b-3d4f060e8a00",
      "content": {
        "id": "5f67a420-c19c-3e35-9c4b-3d4f060e8a00",
        "contentType": "STORY",
        "title": "Radiopharmaceutical specialist Aktis seeks an IPO",
        "description": "",
        "summary": "The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.",
        "pubDate": "2025-12-22T08:56:00Z",
        "displayTime": "2025-12-22T08:56:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xebWKYOkzjDslowFRlBy9Q--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6r2ObCW6Mj9THHRMKUfxsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/aktis-oncology-biotech-ipo-radiopharmaceuticals-nectin-4/808472/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/radiopharmaceutical-specialist-aktis-seeks-ipo-085600017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T16:00:00+00:00",
    "headline": "FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers",
    "summary": "FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported by FlyteHealth's clinically rigorous, outcomes-driven care platform.",
    "url": "https://finance.yahoo.com/news/flytehealth-expand-direct-access-obesity-160000588.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "cb59246d-f3d9-31e8-9b12-b09d5ba86ad6",
      "content": {
        "id": "cb59246d-f3d9-31e8-9b12-b09d5ba86ad6",
        "contentType": "STORY",
        "title": "FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers",
        "description": "",
        "summary": "FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported by FlyteHealth's clinically rigorous, outcomes-driven care platform.",
        "pubDate": "2025-12-22T16:00:00Z",
        "displayTime": "2025-12-22T16:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/0c1286c01ecf366f85838ebc95becd1a",
          "originalWidth": 400,
          "originalHeight": 337,
          "caption": "FlyteHealth (PRNewsfoto/FlyteHealth)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y.8fMHKKt_ayhuc.3EHlzg--~B/aD0zMzc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0c1286c01ecf366f85838ebc95becd1a.cf.webp",
              "width": 400,
              "height": 337,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ny.wc2pKpQE8PuE2J4RUwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0c1286c01ecf366f85838ebc95becd1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/flytehealth-expand-direct-access-obesity-160000588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/flytehealth-expand-direct-access-obesity-160000588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T14:00:07+00:00",
    "headline": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-attracting-140007843.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cad81abc-6093-3241-a061-4e8e27b7ec6a",
      "content": {
        "id": "cad81abc-6093-3241-a061-4e8e27b7ec6a",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
        "pubDate": "2025-12-22T14:00:07Z",
        "displayTime": "2025-12-22T14:00:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ucluz4bedY7Dxd_XS4xCHQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Asv6z7WU__xaJFJkAJhxZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-attracting-140007843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-attracting-140007843.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T17:29:54+00:00",
    "headline": "Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)",
    "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-discusses-major-catalyst-172954837.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "666d6e51-bdea-34c9-966b-73e8f93f0bc0",
      "content": {
        "id": "666d6e51-bdea-34c9-966b-73e8f93f0bc0",
        "contentType": "STORY",
        "title": "Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)",
        "description": "",
        "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry […]",
        "pubDate": "2025-12-22T17:29:54Z",
        "displayTime": "2025-12-22T17:29:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/63a061cb63f19a545df961f541342ced",
          "originalWidth": 1280,
          "originalHeight": 851,
          "caption": "Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kpVxMuVOf.qrgP8VEXLH6Q--~B/aD04NTE7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/63a061cb63f19a545df961f541342ced.cf.webp",
              "width": 1280,
              "height": 851,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q..DQwl.FJSd0we4GohpuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/63a061cb63f19a545df961f541342ced.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-discusses-major-catalyst-172954837.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-discusses-major-catalyst-172954837.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T18:55:52+00:00",
    "headline": "Sector Update: Health Care Stocks Higher in Afternoon Trading",
    "summary": "Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-185552321.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "48207542-ab28-336c-a638-213419ce910d",
      "content": {
        "id": "48207542-ab28-336c-a638-213419ce910d",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Higher in Afternoon Trading",
        "description": "",
        "summary": "Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State",
        "pubDate": "2025-12-22T18:55:52Z",
        "displayTime": "2025-12-22T18:55:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-185552321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-higher-185552321.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "ZBIO"
            },
            {
              "symbol": "ABVX"
            },
            {
              "symbol": "GOOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T18:43:00+00:00",
    "headline": "Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends",
    "summary": "XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.",
    "url": "https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2dc54035-691e-35fa-af3d-c59a4fb8694a",
      "content": {
        "id": "2dc54035-691e-35fa-af3d-c59a4fb8694a",
        "contentType": "STORY",
        "title": "Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends",
        "description": "",
        "summary": "XLV and similar healthcare ETFs are gaining momentum as strength in biotech, increased AI adoption, and rising defensive demand position the sector for year-end leadership.",
        "pubDate": "2025-12-22T18:43:00Z",
        "displayTime": "2025-12-22T18:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3GkkLZFYbl52wnpptRqd1w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a7SzRmhAvDPGiiSvT8MWFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e66aa7ee2b50b297307d131c5d457a73.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bet-top-ranked-healthcare-etfs-184300571.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "VHCIX"
            },
            {
              "symbol": "VHT"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]